A Study of CS3002 in Subjects With Advanced Solid Tumors

Summary

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS3002 in subjects with advanced solid tumors.

Timeline

Start

2019-12-30

Primary completion

2021-02-19

Completion

2021-02-19

Outcome

Outcome not reported

Stopped (Business): “The study has been stopped for strategic and business reasons.”

Drugs

Indications